Gastrointestinal and metabolic function in the MPTP-treated macaque model of Parkinson's disease.
Acetaminophen
FITC-dextran
Gastroparesis
Insulin resistance
Intestinal permeability
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
20
07
2020
revised:
07
10
2020
accepted:
15
12
2020
entrez:
1
1
2021
pubmed:
2
1
2021
medline:
2
1
2021
Statut:
epublish
Résumé
Gastrointestinal (GI) and metabolic function are frequently altered in Parkinson's disease (PD). Although enteric nervous system anatomopathological alterations have previously been reported in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkey model of PD, the resulting gastric emptying and intestinal permeability functional parameters are unknown. The current exploratory study was, thus, designed to investigate these GI functional factors and insulin resistance in the MPTP-treated monkey. Eight rhesus macaque monkeys (4 controls and 4 MPTP-treated) received the oral acetaminophen absorption test to measure gastric emptying, the oral FITC-dextran absorption test to investigate intestinal permeability, and the intravenous glucose tolerance test to assess insulin resistance. Constipation was evaluated using the Bristol stool scale. None of the tests, acetaminophen absorption, FITC-dextran absorption or glucose tolerance, showed a difference between control and MPTP-treated monkeys. MPTP-treated monkeys did present signs of transit acceleration. While the MPTP monkey model reliably displays motor and certain non-motor symptoms of PD, the current study did not demonstrate the GI symptoms associated with PD.
Sections du résumé
BACKGROUND
BACKGROUND
Gastrointestinal (GI) and metabolic function are frequently altered in Parkinson's disease (PD). Although enteric nervous system anatomopathological alterations have previously been reported in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkey model of PD, the resulting gastric emptying and intestinal permeability functional parameters are unknown. The current exploratory study was, thus, designed to investigate these GI functional factors and insulin resistance in the MPTP-treated monkey.
METHODS
METHODS
Eight rhesus macaque monkeys (4 controls and 4 MPTP-treated) received the oral acetaminophen absorption test to measure gastric emptying, the oral FITC-dextran absorption test to investigate intestinal permeability, and the intravenous glucose tolerance test to assess insulin resistance. Constipation was evaluated using the Bristol stool scale.
RESULTS
RESULTS
None of the tests, acetaminophen absorption, FITC-dextran absorption or glucose tolerance, showed a difference between control and MPTP-treated monkeys. MPTP-treated monkeys did present signs of transit acceleration.
CONCLUSION
CONCLUSIONS
While the MPTP monkey model reliably displays motor and certain non-motor symptoms of PD, the current study did not demonstrate the GI symptoms associated with PD.
Identifiants
pubmed: 33385085
doi: 10.1016/j.heliyon.2020.e05771
pii: S2405-8440(20)32614-1
pmc: PMC7772551
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e05771Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
NPJ Parkinsons Dis. 2019 Jun 10;5:10
pubmed: 31231674
Sci Transl Med. 2010 Apr 21;2(28):28ra28
pubmed: 20410529
J Neurosci Methods. 2000 Mar 1;96(1):71-6
pubmed: 10704673
J Parkinsons Dis. 2011;1(2):137-49
pubmed: 23934916
Clin Auton Res. 2019 Aug;29(4):415-425
pubmed: 31338635
Biol Pharm Bull. 2003 Oct;26(10):1442-7
pubmed: 14519952
Food Chem Toxicol. 2020 May;139:111254
pubmed: 32165232
Dig Dis Sci. 2016 Mar;61(3):737-46
pubmed: 26520109
Ann Neurol. 2005 Jan;57(1):17-26
pubmed: 15514976
J Parkinsons Dis. 2019;9(s2):S323-S329
pubmed: 31561386
J Neurosci. 2001 Sep 1;21(17):6853-61
pubmed: 11517273
Clin Pharmacol Ther. 1978 Oct;24(4):420-31
pubmed: 688732
Proc Natl Acad Sci U S A. 2015 May 12;112(19):E2517-26
pubmed: 25918399
PLoS One. 2011;6(12):e28032
pubmed: 22145021
Neurobiol Dis. 2012 Jun;46(3):597-606
pubmed: 22236386
J Vis Exp. 2018 Oct 19;(140):
pubmed: 30394372
Neurology. 2001 Aug 14;57(3):456-62
pubmed: 11502913
Am J Gastroenterol. 2010 Feb;105(2):403-11
pubmed: 19888202
Cereb Cortex. 2015 Sep;25(9):2783-92
pubmed: 24770706
PLoS One. 2014 Jul 14;9(7):e102217
pubmed: 25019507
Nutrients. 2018 May 28;10(6):
pubmed: 29843428
Exp Neurol. 2007 Sep;207(1):4-12
pubmed: 17586496
Br J Pharmacol. 1973 Feb;47(2):415-21
pubmed: 4722050
Lancet Neurol. 2015 Jun;14(6):625-39
pubmed: 25987282
J Pharmacol Toxicol Methods. 1994 Jun;31(3):161-5
pubmed: 8068978
Lancet. 2015 Aug 29;386(9996):896-912
pubmed: 25904081
Aliment Pharmacol Ther. 2016 Oct;44(7):693-703
pubmed: 27492648
Neuron. 2015 Nov 18;88(4):762-73
pubmed: 26590347
Neurogastroenterol Motil. 2009 Feb;21(2):215-22
pubmed: 19077145
Curr Treat Options Neurol. 2018 Oct 25;20(12):54
pubmed: 30361783
Physiol Res. 2019 Apr 30;68(2):295-303
pubmed: 30628835
J Clin Invest. 2012 Nov;122(11):3977-89
pubmed: 23041629
Gut. 2008 Dec;57(12):1741-3
pubmed: 19022934
Nat Med. 2003 Jun;9(6):762-7
pubmed: 12740572
Postgrad Med J. 1996 Mar;72(845):164-7
pubmed: 8731708